Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
News & Analysis: Guardant Health
For a few companies, the second half of 2019 will probably work out better than investors dared hope for earlier this year.
Great Q2 results and higher full-year revenue guidance excited investors.
Even on a day with big swings, these stocks stayed in the green.
The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. Revenue grew 178% in the second quarter, but its plans for the future are even bigger.
GH earnings call for the period ending June 30, 2019.
If you're looking for tremendous growth, these three stocks should have plenty of room to run.
These three businesses are poised to profit from the war on cancer.
These three healthcare stocks are worth checking out right now. Here's why.
These top prospects are more likely to outperform the stock market.